Myofascial Pain:Acupuncture Versus Trigger Point Injection Combined With Dipyrone and Cyclobenzaprine - Full Text View

Sponsor:	Federal University of São Paulo
Information provided by:	Federal University of São Paulo
ClinicalTrials.gov Identifier:	NCT00635037

Purpose

CONTEXT AND OBJECTIVE: Myofascial syndrome is the most frequent condition of chronic pain. The objective of the present study was to compare the analgesic action of acupuncture and trigger point injection combined with cyclobenzaprine and dipyrone.

DESIGN AND SETTING: A randomized study was performed at the Pain Clinic. METHODS: Thirty patients were divided into two groups: G1 received trigger point injection of 0.25% bupivacaine (1 ml/point) twice a week, 10 mg/day cyclobenzaprine and 500 mg dipyrone every 8 h. G2 was submitted to classical and trigger point acupuncture twice a week. The patients were asked to continue physical exercise. The following parameters were evaluated: pain intensity rated on a numerical and verbal scale, quality of life before and four weeks after treatment, and quality of analgesia.

Condition	Intervention
Myofascial Pain Syndromes	Drug: bupivacaine and acupuncture

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Acupuncture Versus Trigger Point Injection Combined With Dipyrone and Cyclobenzaprine on Pain Relief of Patients With Myofascial Pain: Randomized Clinical Study

Resource links provided by NLM:

MedlinePlus related topics: Acupuncture Acute Bronchitis Fibromyalgia

Drug Information available for: Dipyrone Bupivacaine hydrochloride Bupivacaine Cyclobenzaprine Cyclobenzaprine hydrochloride

U.S. FDA Resources

Further study details as provided by Federal University of São Paulo:

Primary Outcome Measures:

Pain relief [ Time Frame: 1year ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

compare the analgesic action of acupuncture and trigger point injection combined with cyclobenzaprine and dipyrone [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

Enrollment:	30
Study Start Date:	June 2004
Study Completion Date:	November 2006
Primary Completion Date:	February 2005 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: A G1 (n=15)received trigger point injection of 0.25% bupivacaine (1 ml/point) twice a week, 10 mg/day cyclobenzaprine and 500 mg dipyrone every 8 h. G2(n=15) was submitted to classical and trigger point acupuncture twice a week.	Drug: bupivacaine and acupuncture trigger point injection of 0.25% bupivacaine (1 ml/point) twice a week, 10 mg/day cyclobenzaprine and 500 mg dipyrone every 8 h. acupuncture twice a week

Detailed Description:

Among the 39 patients selected, nine (3 in group 1 and 6 in group 2) were excluded from the study because they did not attend the visits scheduled for the procedures and assessment or because they did not respond to the questionnaires.

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:- patients of both genders

chronic myofascial syndrome (duration of more than three months),
ranging in age from 18 to 65 year,
pain intensity score of 3 or higher (rated on a numerical scale ranging from 0 to 10)

Exclusion Criteria:

patients with disc herniation,
osteoarthritis,
vertebral collapse,
temporomandibular joint dysfunction,
infection, -
tumors,
coagulopathy, -
psychiatric disease,
cognitive disorders.
Patients who had used any type of analgesic or muscle relaxant agent 15 days before the study and those taking anticoagulants

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00635037

Locations

Brazil
Pain Setor of Federal University of Sao Paulo
Sao Paulo, SP, Brazil

Sponsors and Collaborators

Federal University of São Paulo

Investigators

Principal Investigator:

Miriam CB Gazi, MD

Federal University of Sao Paulo

More Information

No publications provided

Responsible Party:	Adriana Machado Issy/ Professor, Federal University of São Paulo
ClinicalTrials.gov Identifier:	NCT00635037 History of Changes
Other Study ID Numbers:	ACP myofascial, No grant
Study First Received:	March 5, 2008
Last Updated:	March 12, 2008
Health Authority:	Brazil: National Committee of Ethics in Research

Keywords provided by Federal University of São Paulo:

Myofascial pain syndrome
Acupuncture
Nonsteroidal anti-inflammatory agents

Muscle relaxants, central
Quality of life.
muscle relaxants, analgesia

Additional relevant MeSH terms:

Myofascial Pain Syndromes
Fibromyalgia
Somatoform Disorders
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Neuromuscular Diseases
Nervous System Diseases
Mental Disorders
Anti-Inflammatory Agents
Dipyrone
Anti-Inflammatory Agents, Non-Steroidal
Bupivacaine
Cyclobenzaprine
Amitriptyline

Muscle Relaxants, Central
Therapeutic Uses
Pharmacologic Actions
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antirheumatic Agents
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Central Nervous System Agents
Neuromuscular Agents
Antidepressive Agents, Tricyclic

ClinicalTrials.gov processed this record on February 09, 2012